Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: Theravance Biopharma’s 10-K, filed March 23, 2026.
- Filed
- Mar 23, 2026, 8:46 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-033077
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Other long-term liabilities | 67 | (532) |
| Net cash provided by (used in) operating activities | 238,541 | (11,535) |
| Investing activities | ||
| Purchases of property and equipment | (42) | (332) |
| Purchases of marketable securities | (248,217) | (140,743) |
| Maturities of marketable securities | 142,975 | 139,813 |
| Purchase of derivative | — | (2,292) |
| Sale of short-term investments and marketable securities | — | 15,838 |
Item 16. Form 10-K Summary
FAQ
- What is Theravance Biopharma's capex?
- Theravance Biopharma (TBPH) reported capex of $8K in Q4 2025.
- How has Theravance Biopharma's capex changed year-over-year?
- Theravance Biopharma's capex decreased by 95.8% year-over-year, from $190K to $8K.
- What is the long-term trend for Theravance Biopharma's capex?
- Over 3 years (2021 to 2024), Theravance Biopharma's capex has grown at a -54.0% compound annual growth rate (CAGR), from $3.41M to $332K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Theravance Biopharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude